Literature DB >> 27760861

Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

W Oliver Tobin1, Chiara Costanzi1, Yong Guo1, Joseph E Parisi2, Stephen D Weigand3, Claudia F Lucchinetti1.   

Abstract

BACKGROUND: The spectrum of central nervous system-idiopathic inflammatory demyelinating disease (CNS-IIDD) in the elderly is uncertain.
OBJECTIVE: To describe the clinical, radiological, and pathological features of a cohort of 30 pathologically proven CNS-IIDD patients ⩾65 years.
METHODS: Elderly multiple sclerosis (MS)/clinically isolated syndrome (CIS) patients were compared to a cohort of 125 patients with pathologically proven MS/CIS and symptom onset <65 years.
RESULTS: Median age at symptom onset was 69 years (interquartile range (IQR) = 68-75). Median follow-up was 1.9 years (IQR = 1.0-5.6). Diagnoses were MS (14/30), CIS (11/30), neuromyelitis optica (NMO; 4/30), and acute disseminated encephalomyelitis (ADEM; 1/30). Disability was higher in patients with MS/CIS ⩾65 compared to patients <65 (median Expanded Disability Status Scale (EDSS) 4 (IQR = 2.5-7) vs 2.5 (IQR = 1.5-4); p = 0.002). When compared to patients <65 years, there was no difference in the lesion size, number of patients fulfilling Barkhof's criteria, edema, or mass effect. Confluent demyelination was observed in 27 patients (MS/CIS (23/25), NMO (4)), 2 had a mixed perivenular/confluent pattern (MS (1), ADEM (1)), and 1 patient with MS had a mixed confluent/perivenular/coalescent pattern. Early active lesions were found in 19/30 patients ((MS (4), CIS (13), NMO (2); 53%). Cortical demyelination was present in 7/12 (58%) patients (MS (3), CIS(3), ADEM (1)).
CONCLUSION: A spectrum of CNS-IIDD can develop in the elderly, with presenting symptoms similar to younger patients. Early diagnosis of CNS demyelinating disease is essential to avoid invasive and disabling procedures.

Entities:  

Keywords:  Demyelination; acute disseminated encephalomyelitis; autopsy; brain biopsy; elderly; neuromyelitis optica

Mesh:

Year:  2016        PMID: 27760861      PMCID: PMC5376381          DOI: 10.1177/1352458516675748

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  32 in total

1.  Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations.

Authors:  Ian Campbell
Journal:  Stat Med       Date:  2007-08-30       Impact factor: 2.373

2.  The changing face of multiple sclerosis: Prevalence and incidence in an aging population.

Authors:  C Solaro; M Ponzio; E Moran; P Tanganelli; R Pizio; G Ribizzi; S Venturi; G L Mancardi; M A Battaglia
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

4.  Late-onset multiple sclerosis in Isfahan, Iran.

Authors:  Masoud Etemadifar; Seyed-Hossein Abtahi; Alireza Minagar; Mojtaba Akbari; Ali Masaeli; Nasim Tabrizi
Journal:  Arch Iran Med       Date:  2012-10       Impact factor: 1.354

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 6.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

7.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

8.  Natural history of multiple sclerosis in a population-based cohort.

Authors:  M Debouverie; S Pittion-Vouyovitch; S Louis; F Guillemin
Journal:  Eur J Neurol       Date:  2008-07-15       Impact factor: 6.089

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

View more
  1 in total

1.  Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.

Authors:  W Oliver Tobin; Alicja Kalinowska-Lyszczarz; Stephen D Weigand; Yong Guo; Nirubol Tosakulwong; Joseph E Parisi; Imke Metz; Josa M Frischer; Hans Lassmann; Wolfgang Brück; Linda Linbo; Claudia F Lucchinetti
Journal:  Neurology       Date:  2021-09-09       Impact factor: 9.910

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.